Leap therapeutics announces $40 million private placement

Net proceeds, along with existing cash, cash equivalents, and marketable securities are expected to extend cash runway into q2 2026 and enable expansion of dkn-01 defiance clinical trial and development program cambridge, mass. , april 11, 2024 /prnewswire/ -- leap therapeutics, inc. (nasdaq:lptx), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced it has entered into a securities purchase agreement with a select group of institutional investors to issue and sell an aggregate of 12,660,993 shares of its common stock ("common stock") at a price of $2.82 per share and pre-funded warrants to purchase 1,523,404 shares of common stock at a price of $2.819 per share of common stock issuable upon exercise of the pre-funded warrants, in a private placement.
LPTX Ratings Summary
LPTX Quant Ranking